Literature DB >> 16681582

Pseudoscleroderma associated with cancer.

K Kikuchi1, T Hoashi, N Yazawa, K Tamaki.   

Abstract

In the period 1994-2002, we saw 71 patients with sclerotic skin changes; 66 were diagnosed with systemic sclerosis (SSc) while five (7%) were diagnosed with pseudoscleroderma associated with various malignancies. The mean duration of disease in these five patients was significantly shorter than that of patients with SSc. The incidence of positive antinuclear antibodies, Raynaud's phenomenon or oesophageal involvement in patients with pseudoscleroderma was significantly lower than that in patients with SSc. The distributions of skin sclerosis varied in each case. Serum basic fibroblast growth factor (bFGF) levels in the five patients with pseudoscleroderma were very elevated compared with levels in controls. Elevated expression of bFGF was detected on fibroblasts of affected skin and in one lung-cancer tissue sample obtained by excision.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16681582     DOI: 10.1111/j.1365-2230.2006.02092.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  3 in total

Review 1.  Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.

Authors:  Caterina Ferreli; Giulia Gasparini; Aurora Parodi; Emanuele Cozzani; Franco Rongioletti; Laura Atzori
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

2.  Atypical clinical presentation of a subset of patients with anti-RNA polymerase III--non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining.

Authors:  Angela Ceribelli; Malgorzata E Krzyszczak; Yi Li; Steven J Ross; Jason Y F Chan; Edward K L Chan; Rufus W Burlingame; Tyler T Webb; Michael R Bubb; Eric S Sobel; Westley H Reeves; Minoru Satoh
Journal:  Arthritis Res Ther       Date:  2011-07-22       Impact factor: 5.156

Review 3.  [Scleroderma and fibrosing diseases].

Authors:  U A Walker; P Knöss; M Jakobs; V Krenn
Journal:  Z Rheumatol       Date:  2009-06       Impact factor: 1.372

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.